Kim H - Search Results

1

Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control.

Cho M, Choi E, Kim JH, Kim H, Kim HM, Lee JI, Hwang KC, Kim HJ, Han G. Cho M, et al. Among authors: kim h, kim hj, kim hm, kim jh. ChemMedChem. 2014 Mar;9(3):649-56. doi: 10.1002/cmdc.201300393. Epub 2013 Dec 2. ChemMedChem. 2014. PMID: 24376239

2

Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.

Yoon HC, Choi E, Park JE, Cho M, Seo JJ, Oh SJ, Kang JS, Kim HM, Park SK, Lee K, Han G. Yoon HC, et al. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6808-11. doi: 10.1016/j.bmcl.2010.08.117. Epub 2010 Sep 17. Bioorg Med Chem Lett. 2010. PMID: 20850971

3

Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.

Choi E, Lee C, Park JE, Seo JJ, Cho M, Kang JS, Kim HM, Park SK, Lee K, Han G. Choi E, et al. Bioorg Med Chem Lett. 2011 Feb 15;21(4):1218-21. doi: 10.1016/j.bmcl.2010.12.079. Epub 2010 Dec 21. Bioorg Med Chem Lett. 2011. PMID: 21256006

4

Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors: part II.

Lee C, Choi E, Cho M, Lee B, Oh SJ, Park SK, Lee K, Kim HM, Han G. Lee C, et al. Bioorg Med Chem Lett. 2012 Jun 15;22(12):4189-92. doi: 10.1016/j.bmcl.2012.04.045. Epub 2012 Apr 21. Bioorg Med Chem Lett. 2012. PMID: 22578459

5

Property-based optimization of hydroxamate-based γ-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles.

Choi E, Lee C, Cho M, Seo JJ, Yang JS, Oh SJ, Lee K, Park SK, Kim HM, Kwon HJ, Han G. Choi E, et al. J Med Chem. 2012 Dec 13;55(23):10766-70. doi: 10.1021/jm3009376. Epub 2012 Dec 4. J Med Chem. 2012. PMID: 23163332

6

Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.

Cho M, Choi E, Yang JS, Lee C, Seo JJ, Kim BS, Oh SJ, Kim HM, Lee K, Park SK, Kwon HJ, Han G. Cho M, et al. ChemMedChem. 2013 Feb;8(2):272-9. doi: 10.1002/cmdc.201200529. Epub 2013 Jan 4. ChemMedChem. 2013. PMID: 23292995

7

Chemopreventive and chemotherapeutic effect of a novel histone deacetylase inhibitor, by specificity protein 1 in MDA-MB-231 human breast cancer cells.

Shin JA, Han G, Kim HJ, Kim HM, Cho SD. Shin JA, et al. Eur J Cancer Prev. 2014 Jul;23(4):277-85. doi: 10.1097/CEJ.0000000000000041. Eur J Cancer Prev. 2014. PMID: 24871559

8

Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors.

Kim HM, Lee K, Park BW, Ryu DK, Kim K, Lee CW, Park SK, Han JW, Lee HY, Lee HY, Han G. Kim HM, et al. Bioorg Med Chem Lett. 2006 Aug 1;16(15):4068-70. doi: 10.1016/j.bmcl.2006.04.091. Epub 2006 May 24. Bioorg Med Chem Lett. 2006. PMID: 16723227

9

Modification of cap group in delta-lactam-based histone deacetylase (HDAC) inhibitors.

Kim HM, Hong SH, Kim MS, Lee CW, Kang JS, Lee K, Park SK, Han JW, Lee HY, Choi Y, Kwon HJ, Han G. Kim HM, et al. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6234-8. doi: 10.1016/j.bmcl.2007.09.034. Epub 2007 Sep 11. Bioorg Med Chem Lett. 2007. PMID: 17904843

10

A novel gamma-lactam-based histone deacetylase inhibitor potently inhibits the growth of human breast and renal cancer cells.

Kwon HK, Ahn SH, Park SH, Park JH, Park JW, Kim HM, Park SK, Lee K, Lee CW, Choi E, Han G, Han JW. Kwon HK, et al. Biol Pharm Bull. 2009 Oct;32(10):1723-7. doi: 10.1248/bpb.32.1723. Biol Pharm Bull. 2009. PMID: 19801834 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101,691 results

Search Page

Filters